Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
4.19
+0.04 (0.96%)
Dec 19 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 4.05 - 4.25
52 week 2.75 - 4.85
Open 4.13
Vol / Avg. 1,417.00/9,937.00
Mkt cap 133.34M
P/E     -
Div/yield     -
EPS -0.38
Shares 31.82M
Beta 2.07
Inst. own     -
Nov 12, 2014
Q3 2014 Aurinia Pharmaceuticals Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -3500.00% -268.42%
Operating margin -5847.22% -670.50%
EBITD margin - -349.70%
Return on average assets -17.34% -19.23%
Return on average equity -20.14% -46.96%
Employees 26 -
CDP Score - -

Address

1203-4464 Markham St
VICTORIA, BC V8Z 7X8
Canada
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links

Description

Aurinia Pharmaceuticals Inc., formerly Isotechnika Pharma Inc., is an international biopharmaceutical company focused on the discovery and development of therapeutic immunomodulating drug candidates. The Company, together with its partner Lux Biosciences, Inc. (Lux), is investigating its lead drug voclosporin, a calcineurin inhibitor for the prevention of kidney rejection following transplantation, for the treatment of psoriasis, and for ophthalmic diseases, such as uveitis and dye eye syndrome.

Officers and directors

Richard M. Glickman Executive Chairman of the Board
Stephen W. Zaruby President, Chief Executive Officer
Age: 49
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Robert Huizinga Vice President - Clinical Affairs
Charles A. Rowland Jr. Director
Age: 55
Prakash Gowd Independent Director
Age: 48
Donald W. Wyatt Independent Director
Age: 45